Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: Recent progress and future perspective

Future Virology

Volumn 8, Issue 9, 2013, Pages 871-890

  Siccardi, Marco ^a   Rajoli, Rajith Kumar Reddy ^a   Curley, Paul ^a   Olagunju, Adeniyi ^a,b   Moss, Darren ^a   Owen, Andrew ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

Author keywords

antiretrovirals; in vitro in vivo extrapolation; PBPK; pharmacokinetics

Indexed keywords

ALFENTANIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIMALARIAL AGENT; ATAZANAVIR PLUS RITONAVIR; ATRIAL NATRIURETIC FACTOR ALPHA; BISOPROLOL; BOCEPREVIR; CYCLOSPORIN; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; ETIRACETAM; HYDRALAZINE; IMMUNOSUPPRESSIVE AGENT; LIDOCAINE; MILRINONE; MOLSIDOMINE; REPAGLINIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SILDENAFIL; TELITHROMYCIN; THEOPHYLLINE; XENOBIOTIC AGENT;

BLOOD FLOW; COMORBIDITY; DRUG PENETRATION; HEART FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER METABOLISM; MEMBRANE TRANSPORT; METABOLISM; PHYSICAL CHEMISTRY; PREGNANCY; PRIORITY JOURNAL; REVIEW;

EID: 84883236782     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.13.67     Document Type: Review

References (181)

1. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15(1), 71-75 (2001
2. Stahle L, Moberg L, Svensson JO, Sonnerborg A. Efavirenz plasma concentrations in HIV-infected patients: Inter- and intraindividual variability and clinical effects. Ther. Drug Monit. 26(3), 267-270 (2004
3. Josephson F, Andersson MC, Flamholc L et al. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naive HIV-1 infected patients. Eur. J. Clin. Pharmacol. 66(4), 349-357 (2010
4. Gonzalez de Requena D, Bonora S, Vigano O et al. Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. J. Antimicrob. Chemother. 66(1), 192-200 (2011
5. Hoefnagel JG, van der Lee MJ, Koopmans PP et al. The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy. AIDS 20(7), 1069-1071 (2006
6. Marzolini C, Elzi L, Gibbons S et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir. Ther. 15(3), 413-423 (2010
7. Marzolini C, Back D, Weber R et al. Ageing with HIV: Medication use and risk for potential drug-drug interactions. J. Antimicrob. Chemother. 66(9), 2107-2111 (2011
8. Bosgra S, van Eijkeren J, Bos P, Zeilmaker M, Slob W. An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometry. Crit. Rev. Toxicol. 42(9), 751-767 (2012
9. Peters S. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin. Pharmacokinet. 47(4), 261-275 (2008
10. Teorell T. Kinetics of distribution of substances administered to the body. I. The extravascular modes of administration. Arch. Int. Pharmacod. 57, 205-225 (1937
11. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Ann. Rev. Pharmacol. Toxicol. 51(1), 45-73 (2011
12. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J. Pharmacol. Exp. Ther. 306(2), 703-708 (2003
13. Evers R, Kool M, van Deemter L et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Invest. 101(7), 1310-1319 (1998
14. Walgren RA, Karnaky KJ Jr, Lindenmayer GE, Walle T. Efflux of dietary flavonoid quercetin 4'-beta-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. J. Pharmacol. Exp. Ther. 294(3), 830-836 (2000
15. Lagas JS, Vlaming ML, Schinkel AH. Pharmacokinetic assessment of multiple ATP-binding cassette transporters: The power of combination knockout mice. Mol. Interv. 9(3), 136-145 (2009
16. Thelen K, Dressman JB. Cytochrome P450-mediated metabolism in the human gut wall. J. Pharm. Pharmacol. 61(5), 541-558 (2009
17. Hartkoorn RC, Kwan WS, Shallcross V et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet. Genomics 20(2), 112-120 (2010
18. Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 91(1), 129-156 (2002
19. Brightman FA, Leahy DE, Searle GE, Thomas S. Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma. Drug Metab. Dispos. 34(1), 94-101 (2006
20. Parrott N, Paquereau N, Coassolo P, Lavé T. An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. J. Pharm. Sci. 94(10), 2327-2343 (2005
21. Bouzom F, Ball K, Perdaems N, Walther B. Physiologically based pharmacokinetic (PBPK) modelling tools: How to fit with our needs? Biopharm. Drug Dispos. 33(2), 55-71 (2012
22. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A. The Simcyp population-based ADME simulator. Expert Opin. Drug Metab. Toxicol. 5(2), 211-223 (2009
23. Jones H, Parrott N, Ohlenbusch G, Lavé T. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling. Clin. Pharmacokinet. 45(12), 1213-1226 (2006
24. Reddy MB, Clewell III HJ, Lave T, Andersen ME. Physiologically based pharmacokinetic modeling: A tool for understanding ADMET properties and extrapolating to human. In: New Insights into Toxicity and Drug Testing. Gowder S (Ed.). InTech, NY, USA, 197-217 (2013
25. Blehar MC, Spong C, Grady C, Goldkind SF, Sahin L, Clayton JA. Enrolling pregnant women: Issues in clinical research. Womens Health Issues 23(1), e39-e45 (2013
26. Anderson GD. Pregnancy-induced changes in pharmacokinetics: A mechanistic-based approach. Clin. Pharmacokinet. 44(10), 989-1008 (2005
27. Buckoreelall K, Cressey TR, King Jr. Pharmacokinetic optimization of antiretroviral therapy in pregnancy. Clin. Pharmacokinet. 51(10), 639-659 (2012
28. Olagunju A, Owen A, Cressey TR. Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. Pharmacogenomics 13(13), 1501-1522 (2012
29. WHO. PMTCT Strategic Vision 2010-2015: Preventing Mother-to-Child Transmission of HIV to Reach the UNGASS and Millennium Development Goals. WHO Press, Geneva, Switzerland (2010
30. Drocourt L, Ourlin JC, Pascussi JM, Maurel P, Vilarem MJ. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J. Biol. Chem. 277(28), 25125-25132 (2002
31. Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: A database for parameters required in physiologically based pharmacokinetic modelling. Clin. Pharmacokinet. 51(6), 365-396 (2012
32. Gaohua L, Abduljalil K, Jamei M, Johnson TN, Rostami-Hodjegan A. A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. Br. J. Clin. Pharmacol. 74(5), 873-885 (2012
33. Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Unadkat JD. A PBPK model to predict disposition of CYP3A-metabolized drugs in pregnant women: Verification and discerning the site of CYP3A induction. CPT Pharmacometrics Syst. Pharmacol. 1, e3 (2012
34. Cressey TR, Best BM, Achalapong J. Effect of pregnancy on pharmacokinetics of indinavir boosted ritonavir. Presented at: 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, Spain, 16-18 April 2012
35. WHO. Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access. WHO Press, Geneva, Switzerland (2010
36. Persaud D, Gay H, Ziemniak C et al. Functional HIV cure after very early ART of an infected infant. Presented at: 20th Conference on Retroviruses and Opportunistic Infections (CROI). Atlanta, GA, USA, 3-6 March 2013
37. Luzuriaga K, Chen Y, Ziemniak C et al. Absent HIV-specific immune responses and replication-competent HIV reservoirs in perinatally infected youth treated from infancy: Towards cure. Presenetd at: 20th Conference on Retroviruses and Opportunistic Infections (CROI). Atlanta, GA, USA, 3-6 March 2013
38. Johnson TN. The problems in scaling adult drug doses to children. Arch. Dis. Child. 93(3), 207-211 (2008
39. Fillekes Q, Mulenga V, Kabamba D et al. Is nevirapine dose escalation appropriate in young, African, HIV-infected children? AIDS doi:10.1097/QAD. 0b013e3283620811 (2013) (Epub ahead of print
40. Fillekes Q, Natukunda E, Balungi J et al. Pediatric underdosing of efavirenz: A pharmacokinetic study in Uganda. J. Acquir. Immune Defic. Syndr. 58(4), 392-398 (2011
41. Zoufaly A, Fillekes Q, Hammerl R et al. Prevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: A cross-sectional study. Antivir. Ther. doi:10.3851/IMP2562 (2013) (Epub ahead of print
42. Maharaj AR, Barrett JS, Edginton AN. A workflow example of PBPK modeling to support pediatric research and development: Case study with lorazepAm. AAPS J. 15(2), 455-464 (2013
43. Basic anatomical and physiological data for use in radiological protection: Reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann. ICRP 32(3-4), 5-265 (2002
44. Bjorkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: Theophylline and midazolam as model drugs. Br. J. Clin. Pharmacol. 59(6), 691-704 (2005
45. Siccardi M, Almond L, Khoo S, Owen A, Back D. Pharmacokinetics of efavirenz dose optimization in pediatric patients using an in vitro in vivo extrapolation model. Presented at: 19th Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, WA, USA, 5-8 March 2012
46. Donegan K, Doerholt K, Judd A et al. Lopinavir dosing in HIV-infected children in the United Kingdom and Ireland. Pediatr. Infect. Dis. J. 32(1), 45-50 (2013
47. Foxenberg RJ, Ellison CA, Knaak JB, Ma C, Olson Jr. Cytochrome P450-specific human PBPK/PD models for the organophosphorus pesticides: Chlorpyrifos and parathion. Toxicology 285(1-2), 57-66 (2011
48. High KP, Brennan-Ing M, Clifford DB et al. HIV and aging: State of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J. Acquir. Immune Defic. Syndr. 60(Suppl. 1), S1-S18 (2012
49. Hontelez JA, de Vlas SJ, Baltussen R et al. The impact of antiretroviral treatment on the age composition of the HIV epidemic in sub-Saharan Africa. AIDS 26(Suppl. 1), S19-S30 (2012
50. Cusack BJ. Pharmacokinetics in older persons. Am. J. Geriatr. Pharmacother. 2(4), 274-302 (2004
51. Rhee MS, Greenblatt DJ. Pharmacologic consideration for the use of antiretroviral agents in the elderly. J. Clin. Pharmacol. 48(10), 1212-1225 (2008
52. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab. Rev. 41(2), 67-76 (2009
53. Schoen JC, Erlandson KM, Anderson PL. Clinical pharmacokinetics of antiretroviral drugs in older persons. Expert Opin. Drug Metab. Toxicol. 9(5), 573-588 (2013
54. van Assema DM, Lubberink M, Boellaard R et al. P-glycoprotein function at the blood-brain barrier: Effects of age and gender. Mol. Imaging Biol. 14(6), 771-776 (2012
55. Bartels AL, Kortekaas R, Bart J et al. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: A possible role in progressive neurodegeneration. Neurobiol. Aging 30(11), 1818-1824 (2009
56. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270(1), 414-423 (1994
57. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol. Appl. Pharmacol. 199(3), 193-209 (2004
58. Crawford KW, Spritzler J, Kalayjian RC et al. Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. AIDS Res. Hum. Retroviruses 26(6), 635-643 (2010
59. Winston A, Jose S, Gibbons S et al. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. J. Antimicrob. Chemother. 68(6), 1354-1359 (2013
60. Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin. Pharmacokinet. 47(5), 297-321 (2008
61. Blizard D, Sueyoshi T, Negishi M, Dehal SS, Kupfer D. Mechanism of induction of cytochrome P450 enzymes by the proestrogenic endocrine disruptor pesticide-methoxychlor: Interactions of methoxychlor metabolites with the constitutive androstane receptor system. Drug Metab. Dispos. 29(6), 781-785 (2001
62. Thompson CM, Johns DO, Sonawane B et al. Database for physiologically based pharmacokinetic (PBPK) modeling: Physiological data for healthy and health-impaired elderly. J. Toxicol. Environ. Health B Crit. Rev. 12(1), 1-24 (2009
63. Puoti M, Moioli MC, Travi G, Rossotti R. The burden of liver disease in human immunodeficiency virus-infected patients. Semin. Liver Dis. 32(2), 103-113 (2012
64. Ogawa R, Stachnik JM, Echizen H. Clinical pharmacokinetics of drugs in patients with heart failure: An update (part 1, drugs administered intravenously). Clin. Pharmacokinet. 52(3), 169-185 (2013
65. Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J. Pharmacol. Exp. Ther. 256(3), 1189-1194 (1991
66. Kojima H, Nies AT, Konig J et al. Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J. Hepatol. 39(5), 693-702 (2003
67. Iwasa M, Nakamura K, Nakagawa T et al. Single photon emission computed tomography to determine effective hepatic blood flow and intrahepatic shunting. Hepatology 21(2), 359-365 (1995
68. Blaschke TF. Protein binding and kinetics of drugs in liver diseases. Clin. Pharmacokinet. 2(1), 32-44 (1977
69. Fagundes C, Gines P. Hepatorenal syndrome: A severe, but treatable, cause of kidney failure in cirrhosis. Am. J. Kidney Dis. 59(6), 874-885 (2012
70. Gines P, Schrier RW. Renal failure in cirrhosis. N. Engl. J. Med. 361(13), 1279-1290 (2009
71. Barreiro P, Rodriguez-Novoa S, Labarga P et al. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J. Infect. Dis. 195(7), 973-979 (2007
72. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur. J. Clin. Pharmacol. 64(12), 1147-1161 (2008
73. Li GF, Wang K, Chen R, Zhao HR, Yang J, Zheng QS. Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling. Acta Pharmacol. Sin. 33(11), 1359-1371 (2012
74. Zhao P, Vieira MDT, Grillo JA et al. Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J. Clin. Pharmacol. 52(1 Suppl.), 91S-108S (2012
75. Edginton AN, Willmann S. Physiology-based simulations of a pathological condition: Prediction of pharmacokinetics in patients with liver cirrhosis. Clin. Pharmacokinet. 47(11), 743-752 (2008
76. Crum-Cianflone N, Roediger MP, Eberly L et al. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PloS ONE 5(4), e10106 (2010
77. Mandina Ndona M, Longo-Mbenza B, Wumba R et al. Nadir CD4+, religion, antiretroviral therapy, incidence of Type 2 diabetes mellitus, and increasing rates of obesity among black Africans with HIV disease. Int. J. Gen. Med. 5, 983-990 (2012
78. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin. Pharmacokinet. 49(2), 71-87 (2010
79. Morrish GA, Pai MP, Green B. The effects of obesity on drug pharmacokinetics in humans. Expert Opin. Drug Metab. Toxicol. 7(6), 697-706 (2011
80. de Roche M, Siccardi M, Stoeckle M et al. Efavirenz in an obese HIV-infected patient - A report and an in vitro-in vivo extrapolation model indicate risk of underdosing. Antivir. Ther. 17(7), 1381-1384 (2012
81. Tseng A, Hills-Nieminen C. Drug interactions between antiretrovirals and hormonal contraceptives. Expert Opin. Drug Metab. Toxicol. 9(5), 559-572 (2013
82. Byakika-Kibwika P, Lamorde M, Mayito J et al. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J. Antimicrob. Chemother. 67(9), 2213-2221 (2012
83. Byakika-Kibwika P, Lamorde M, Okaba-Kayom V et al. Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults. J. Antimicrob. Chemother. 67(5), 1217-1223 (2012
84. Soyinka JO, Onyeji CO. Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz. Eur. J. Pharm. Sci. 39(4), 213-218 (2010
85. Soyinka JO, Onyeji CO, Omoruyi SI, Owolabi AR, Sarma PV, Cook JM. Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. J. Pharm. Pharmacol. 61(4), 439-443 (2009
86. Soyinka JO, Onyeji CO, Omoruyi SI, Owolabi AR, Sarma PV, Cook JM. Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. Br. J. Clin. Pharmacol. 69(3), 262-270 (2010
87. Carten ML, Kiser JJ, Kwara A, Mawhinney S, Cu-Uvin S. Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and efavirenz. Infect. Dis. Obstet. Gynecol. 2012, 137192 (2012
88. Chu X, Cai X, Cui D et al. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metab. Dispos. 41(3), 668-681 (2013
89. Hulskotte EG, Feng HP, Xuan F et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin. Infect. Dis. 56(5), 718-726 (2013
90. van Heeswijk RP, Beumont M, Kauffman RS, Garg V. Review of drug interactions with telaprevir and antiretrovirals. Antivir. Ther. doi:10.3851/IMP2527 (2013) (Epub ahead of print
91. Vourvahis M, Plotka A, Kantaridis C. The effect of boceprevir and telaprevir on the pharmacokinetics of maraviroc: An open-label, fixed-sequence study in healthy volunteers. Presented at: 14th International Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam, The Netherlands, 22-24 April 2013
92. Nwebaza N, Kajubi R, Ssebuliba J et al. Selection of ARV regimen impacts antimalarial pharmacokinetics and treatment outcomes in HIV/malaria co-infected children in Uganda. Presented at: 20th Conference on Retroviruses and Opportunistic Infections (CROI). Atlanta, GA, USA, 3-6 March 2013
93. Siccardi M, Olagunju A, Seden K et al. Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. In Silico Pharmacol. 1, 4 (2013
94. Siccardi M, Marzolini C, Seden K et al. Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. Clin. Pharmacokinet. 52(7), 583-592 (2013
95. Nachega JB, Hsu AJ, Uthman OA, Spinewine A, Pham PA. Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. AIDS 26(Suppl. 1), S39-S53 (2012
96. Orlando G, Meraviglia P, Cordier L et al. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med. 7(8), 549-557 (2006
97. Negin J, Martiniuk A, Cumming RG et al. Prevalence of HIV and chronic comorbidities among older adults. AIDS 26(Suppl. 1), S55-S63 (2012
98. Grillo JA, Zhao P, Bullock J et al. Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: Implications for clinical practice. Biopharm. Drug Dispos. 33(2), 99-110 (2012
99. van den Bout-van den Beukel CJ, Koopmans PP, van der Ven AJ, De Smet PA, Burger DM. Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents. Drug Metab. Rev. 38(3), 477-514 (2006
100. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3(8), 711-715 (2004
101. Lennernas H, Abrahamsson B. The use of biopharmaceutic classification of drugs in drug discovery and development: Current status and future extension. J. Pharm. Pharmacol. 57(3), 273-285 (2005
102. van Klooster G, Hoeben E, Borghys H et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob. Agents Chemother. 54(5), 2042-2050 (2010
103. Kashuba AD. Drug-drug interactions and the pharmacotherapy of HIV infection. Top. HIV Med. 13(2), 64-69 (2005
104. Fang AF, Damle BD, LaBadie RR, Crownover PH, Hewlett D Jr, Glue PW. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects. Pharmacotherapy 28(1), 42-50 (2008
105. Iwamoto M, Wenning LA, Nguyen BY et al. Effects of omeprazole on plasma levels of raltegravir. Clin. Infect. Dis. 48(4), 489-492 (2009
106. Jamei M, Turner D, Yang J et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 11(2), 225-237 (2009
107. Darwich AS, Neuhoff S, Jamei M, Rostami-Hodjegan A. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: A simulation assessment using the 'advanced dissolution, absorption, metabolism (ADAM)' model. Curr. Drug Metab. 11(9), 716-729 (2010
108. Allan G, Davis J, Dickins M et al. Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man. Xenobiotica 38(6), 620-640 (2008
109. Lake-Bakaar G, Tom W, Lake-Bakaar D et al. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 109(6), 471-473 (1988
110. Moss DM, Siccardi M, Back DJ, Owen A. Predicting intestinal absorption of raltegravir using a population-based ADME simulation. J. Antimicrob. Chemother. 68(7), 1627-1634 (2013
111. Moss DM, Siccardi M, Murphy M et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob. Agents Chemother. 56(6), 3020-3026 (2012
112. Kiser JJ, Bumpass JB, Meditz AL et al. Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob. Agents Chemother. 54(12), 4999-5003 (2010
113. Darwich AS, Pade D, Ammori BJ, Jamei M, Ashcroft DM, Rostami-Hodjegan A. A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: Interplay between CYP3A gut wall metabolism, permeability and dissolution. J. Pharm. Pharmacol. 64(7), 1008-1024 (2012
114. Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br. J. Clin. Pharmacol. 56(1), 120-124 (2003
115. Thorn M, Finnstrom N, Lundgren S, Rane A, Loof L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br. J. Clin. Pharmacol. 60(1), 54-60 (2005
116. Schiller C, Frohlich CP, Giessmann T et al. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment. Pharmacol. Ther. 22(10), 971-979 (2005
117. Sousa T, Paterson R, Moore V, Carlsson A, Abrahamsson B, Basit AW. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int. J. Pharm. 363(1-2), 1-25 (2008
118. Shelton MJ, Akbari B, Hewitt RG, Adams JM, Morse GD. Eradication of Helicobacter pylori is associated with increased exposure to delavirdine in hypochlorhydric HIV-positive patients. J. Acquir. Immune Defic. Syndr. 24(1), 79-82 (2000
119. Chave JP, Thorens J, Frohlich F et al. Gastric and duodenal bacterial colonization in HIV-infected patients without gastrointestinal symptoms. Am. J. Gastroenterol. 89(12), 2168-2171 (1994
120. Linskens RK, Huijsdens XW, Savelkoul PH, Vandenbroucke-Grauls CM, Meuwissen SG. The bacterial flora in inflammatory bowel disease: Current insights in pathogenesis and the influence of antibiotics and probiotics. Scand. J. Gastroenterol. Suppl. (234), 29-40 (2001
121. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: Human gut microbes associated with obesity. Nature 444(7122), 1022-1023 (2006
122. Cory TJ, Schacker TW, Stevenson M, Fletcher CV. Overcoming pharmacologic sanctuaries. Curr. Opin. HIV AIDS 8(3), 190-195 (2013
123. Marzolini C, Gray GE. Maternal antiretroviral prophylaxis and breastfeeding. Antivir. Ther. 17(8), 1503-1506 (2012
124. Clewell RA, Gearhart JM. Pharmacokinetics of toxic chemicals in breast milk: Use of PBPK models to predict infant exposure. Environ. Health Perspect. 110(6), A333-A337 (2002
125. Janneh O, Hartkoorn R, Jones E et al. Cultured CD4T cells and primary human lymphocytes express hOATPs: Intracellular accumulation of saquinavir and lopinavir. Br. J. Pharmacol. 155(6), 875-883 (2008
126. Smith NF, Figg WD, Sparreboom A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin. Drug Metab. Toxicol. 1(3), 429-445 (2005
127. Obaidat A, Roth M, Hagenbuch B. The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu. Rev. Pharmacol. Toxicol. 52, 135-151 (2012
128. Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 123(5), 369-375 (2003
129. Nakamura A, Nakajima M, Yamanaka H, Fujiwara R, Yokoi T. Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab. Dispos. 36(8), 1461-1464 (2008
130. Liu X, Tu M, Kelly RS, Chen C, Smith BJ. Development of a computational approach to predict blood-brain barrier permeability. Drug Metab. Dispos. 32(1), 132-139 (2004
131. Ene L, Duiculescu D, Ruta S. How much do antiretroviral drugs penetrate into the central nervous system? J. Med. Life 4(4), 432 (2011
132. Letendre S, Marquie-Beck J, Capparelli E et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch. Neurol. 65(1), 65-70 (2008
133. Marra CM, Zhao Y, Clifford DB et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23(11), 1359-1366 (2009
134. Tozzi V, Balestra P, Salvatori MF et al. Changes in cognition during antiretroviral therapy: Comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J. Acquir. Immune Defic. Syndr. 52(1), 56-63 (2009
135. Letendre S. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top. Antivir. Med. 19(4), 137-142 (2011
136. Thomas S. Anti-HIV drug distribution to the central nervous system. Curr. Pharm. Des. 10(12), 1313-1324 (2004
137. Westerhout J, Ploeger B, Smeets J, Danhof M, de Lange EC. Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. AAPS J. 14(3), 543-553 (2012
138. Curley P, Martin P, Liptrott N, Back D, Owen A, Siccardi M. Utilising in vitro-in vivo extrapolation to investigate efavirenz penetration into the central nervous system. Presented at: 14th International Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam, The Netherlands, 22-24 April 2013
139. Owen A, Pirmohamed M, Khoo SH, Back DJ. Pharmacogenetics of HIV therapy. Pharmacogenet. Genomics 16(10), 693-703 (2006
140. Desta Z, Saussele T, Ward B et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8(6), 547-558 (2007
141. Siccardi M, D'Avolio A, Nozza S et al. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. Pharmacogenet. Genomics 20(12), 759-765 (2010
142. Thompson MA, Aberg JA, Cahn P et al. Antiretroviral treatment of adult HIV infection. JAMA 304(3), 321-333 (2010
143. Mahungu T, Johnson M, Owen A, Back D. The impact of pharmacogenetics on HIV therapy. Int. J. STD AIDS 20(3), 145-151 (2009
144. Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentre F, Taburet AM. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin. Pharmacokinet. 49(1), 17-45 (2010
145. von Kleist M, Huisinga W. Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape: An example based on zidovudine. Eur. J. Pharm. Sci. 36(4), 532-543 (2009
146. Hurwitz SJ, Asif G, Schinazi RF. Development of a population simulation model for HIV monotherapy virological outcomes using lamivudine. Antivir. Chem. Chemother. 18(6), 329-342 (2007
147. Zhang W, Yu BN, He Y-J et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chim. Acta 373(1), 99-103 (2006
148. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV infected adults. HIV Med. 9(2), 65-71 (2008
149. Schipani A, Wyen C, Mahungu T et al. Integration of population pharmacokinetics and pharmacogenetics: An aid to optimal nevirapine dose selection in HIV-infected individuals. J. Antimicrob. Chemother. 66(6), 1332-1339 (2011
150. Elens L, Vandercam B, Yombi J, Lison D, Wallemacq P, Haufroid V. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics 11(9), 1223-1234 (2010
151. Rotger M, Colombo S, Furrer H et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics 15(1), 1-5 (2005
152. Ogburn ET, Jones DR, Masters AR, Xu C, Guo YY, Desta Z. Efavirenz primary and secondary metabolism in vitro and in vivo: Identification of novel metabolic pathways and cytochrome P450 (CYP) 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab. Dispos. 38(7), 1218-1229 (2010
153. Bae S, Jeong YJ, Lee C, Liu KH. Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites. Xenobiotica 41(6), 437-444 (2011
154. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306(1), 287-300 (2003
155. Haas D, Ribaudo H, Kim R et al. Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS 18(18), 2391-2400 (2004
156. Rakhmanina N, van den Anker J. Efavirenz in the therapy of HIV infection. Expert Opin. Drug Metab. Toxicol. 6(1), 95-103 (2010
157. Siccardi M, Almond L, Schipani A et al. Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model. Clin. Pharmacol. Ther. 92(4), 494-502 (2012
158. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab. Dispos. 27(12), 1488-1495 (1999
159. Calcagno A, D'Avolio A, Simiele M et al. Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. Br. J. Clin. Pharmacol. 74(1), 134-140 (2012
160. Croxtall JD. Etravirine: A review of its use in the management of treatment-experienced patients with HIV-1 infection. Drugs 72(6), 847-869 (2012
161. Schöller-Gyüre M, Kakuda TN, De Smedt G et al. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers. Br. J. Clin. Pharmacol. 66(4), 508-516 (2008
162. Siccardi M, Olagunju A, Curley P et al. Prediction of etravirine pharmacogenetics using a physiologically based pharmacokinetic approach. Presented at: 20th Conference on Retroviruses and Opportunistic Infections (CROI). Atlanta, GA, USA, 3-6 March 2013
163. Lubomirov R, Arab-Alameddine M, Rotger M et al. Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. Pharmacogenet. Genomics 23(1), 9-18 (2013
164. Fröhlich M, Hoffmann MM, Burhenne J, Mikus G, Weiss J, Haefeli WE. Association of the CYP3A5 A6986G (CYP3A5.*3) polymorphism with saquinavir pharmacokinetics. Br. J. Clin. Pharmacol. 58(4), 443-444 (2004
165. Ke A, Nallani S, Zhao P, Rostami-Hodjegan A, Unadkat J. A PBPK model to predict disposition of CYP3A-metabolized drugs in pregnant women: Verification and discerning the site of CYP3A induction. CPT Pharmacometrics Syst. Pharmacol. 1(9), e3 (2012
166. Zhao P, Rowland M, Huang SM. Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin. Pharmacol. Ther. 92(1), 17-20 (2012
167. Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: A pilot study. J. Acquir. Immune Defic. Syndr. 42(4), 441-449 (2006
168. Gradhand U, Lang T, Schaeffeler E et al. Variability in human hepatic MRP4 expression: Influence of cholestasis and genotype. Pharmacogenomics J. 8(1), 42-52 (2007
169. Rodriguez-Novoa S, Labarga P, Soriano V. Pharmacogenetics of tenofovir treatment. Pharmacogenomics 10(10), 1675-1685 (2009
170. Pushpakom SP, Liptrott NJ, Rodriguez-Novoa S et al. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J. Infect. Dis. 204(1), 145-153 (2011
171. Mahungu T, Smith C, Turner F et al. Cytochrome P450 2B6 516G->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med. 10(5), 310-317 (2009
172. Wyen C, Hendra H, Vogel M et al. Impact of CYP2B6 983T> C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J. Antimicrob. Chemother. 61(4), 914-918 (2008
173. Wang J, Sönnerborg A, Rane A et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet. Genomics 16(3), 191-198 (2006
174. Liptrott NJ, Pushpakom S, Wyen C et al. Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenet. Genom. 22(1), 10-19 (2012
175. Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 23(16), 2101-2106 (2009
176. Cortes CP, Siccardi M, Chaikan A, Owen A, Zhang G, Porte CJ. Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor. Ther. Drug Monit. 35(1), 78-83 (2012
177. Wyen C, Hendra H, Siccardi M et al. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J. Antimicrob. Chemother. 66(9), 2092-2098 (2011
178. Haufroid V, Mourad M, Van Kerckhove V et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenet. Genomics 14(3), 147-154 (2004
179. Josephson F, Allqvist A, Janabi M et al. CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin. Pharmacol. Ther. 81(5), 708-712 (2007
180. Schipani A, Siccardi M, D'Avolio A et al. Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob. Agents Chemother. 54(12), 5242-5250 (2010
181. Siccardi M, D'Avolio A, Baietto L et al. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C ->T) with reduced concentrations of unboosted atazanavir. Infect. Cont. Hosp. Ep. 29, 1222-1225 (2008